No profile data available.
Shaperon Inc. (378800.KQ) is a healthcare company in the brain and nerve treatment drugs industry, based in Seoul, South Korea.
It reported revenue of $227.80 million for fiscal year 2025, up 1186.7% from fiscal year 2024, and net income of -$15.53 billion. Its market capitalization was 18.37 billion KRW as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases.
Shaperon reported $227.80 million in revenue for fiscal year 2025, up 1186.7% from 17.70 million KRW in fiscal year 2024.
18.37 billion KRW as of October 8, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include SK Biopharmaceuticals Co., Ltd. (326030.KS), Whan In Pharm Co.,Ltd. (016580.KS), Korean Drug Co., Ltd. (014570.KQ).